Aft banks on stronger second half as strike and destocking hit first-half result

Aft banks on stronger second half as strike and destocking hit first-half result
Hartley Atkinson says Aft should have a new licensing deal for its Maxigesic pain relief soon. (Image: Aft Pharmaceuticals)
Rebecca Stevenson
Aft Pharmaceuticals is pinning its hopes on a stronger second-half result after a $2.46 million loss for the six months to Sept 30. The New Zealand Exchange (NZX) listed pharmaceutical manufacturer said its result was affected by a doctor strike in South Korea and several large customers reducing stock. These caused a $6.5m hit to product sales and royalties in Aft’s Asian and other international markets, the company said.Sales of its Maxigesic intravenous line were significantly affected by the now-resolved doctors' strike....

More Markets

NZ sharemarket down 0.1% on inflation news
Markets Market Close

NZ sharemarket down 0.1% on inflation news

The S&P/NZX 50 Index closed at 13,019.83, down 15.76 points or 0.12%.

Govt support needed to make sustainable aviation fuel
Markets

Govt support needed to make sustainable aviation fuel

Other countries may hesitate to export sustainable aviation fuel to NZ.

Too few NZ ports earning 'appropriate returns'
Infrastructure

Too few NZ ports earning 'appropriate returns'

Port returns over the past decade 'disappointing and alarming'.